СПСофия Георгиевна Попович

София Георгиевна Попович

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


София Георгиевна Попович has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical experience of treating 28 patients with Duchenne muscular dystrophy with the exon 45 skipping drug casimersen

    by A. A. Agafonova, Агафонова А. А., S. B. Artemyeva, Артемьева С. Б., D. V. Vlodavets, Влодавец Д. В., L. M. Kuzenkova, Кузенкова Л. М., L. I. Minaycheva, Минайчева Л. И., et al.

    Background. Duchenne muscular dystrophy (DMD) is an irreversible, progressive fatal genetic disorder caused by the absence of functional dystrophin protein in muscle due to mutations in the DMD gene. Exon-skipping therapy for DMD aims to increase the amount of functionally active protein dystrophin. Casimersen, a drug for skipping exon 45, is indicated for patients with certain deletions. Clinical studies have confirmed an increase in dystrophin levels and improved motor activity in patients with DMD treated with casimersen. Aim. To present the experience of treating patients with DMD who were eligible for exon 45 skipping therapy. Materials and methods. Twenty-eight patients with DMD who received exon 45 skipping therapy were observed. Patients were assessed for functional status, motor tests (Six-Minute Walk Test, North Star Ambulatory Assessment) dynamics, and respiratory function with dynamic assessment of functional vital capacity. Results. Most outpatients showed stabilization of their condition with preservation of the ability to move independently, improvement or stability in functional (Six-Minute Walk Test, North Star Ambulatory Assessment) and timed test indicators, as well as stabilization of upper limb function and absence of progression of respiratory function decline in non-ambulatory patients. Conclusion. The safety and tolerability of casimersen therapy were generally good in all patients with DMD in our sample. All patients who initiated casimersen therapy in the early outpatient stage remained in this stage at the analysis date.

  • Open Access

    Results of a Two-Year Comprehensive Follow-Up of Patients with Spinal Muscular Atrophy Type I Who Received Gene Therapy with Onasemnogen Abeparvovek

    by A. L. Kurenkov, L. M. Kuzenkova, E. V. Uvakina, V. V. Chernikov, S. G. Popovich, D. A. Fisenko, B. I. Bursagova, O. V. Globa, N. V. Andreenko, L. M. Abdullaeva, et al.

    Introduction . Spinal muscular atrophy (SMA) is among the most severe inherited neuromuscular diseases. The development of pathogenetic treatment methods, including gene therapy, and their widespread clinical adoption has ushered in a new era in SMA treatment, making it possible not only to halt the progression of the disease but also to improve patients’ functional capabilities. Aim : to evaluate the efficacy of gene therapy in a real-world clinical practice with a 2-year follow-up study of patients with SMA type I who received treatment with onasemnogene abeparvovec. Materials and methods . The study included 73 patients with SMA type I. The disease was confirmed by molecular genetic testing.The diagnosis of SMA type I in 22 patients (30.1%) was established due to the development of the clinical picture of the disease and after confirmatory DNA diagnostics. In 51 patients (69.9%), initially identified as part of expanded neonatal screening, the diagnosis was established immediately after the onset of the first SMA symptoms. The mean age at the time of gene therapy was 2.78±1.87 months (95% CI 2.35–3.22), min 1.00, max 7.00. A comprehensive assessment of treatment effectiveness included clinical (the main the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores) and electroneuromyographic (latency, amplitude and area of the negative peak of the distal compound muscle action potential during electrical stimulation of the ulnar nerve at the wrist, the motor nerve conduction velocity of the ulnar nerve on the forearm) parameters before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results . Following gene therapy, a large number of patients with SMA type I were able to achieve basic motor skills: 42.5% had good head control in the prone position; 78.1% rolled over from a supine to prone position; 47.2% sitting without support; 31.9% standing with assistance; 23.2% hands-&-knees crawling; 20.0% walking with assistance; 13.2% standing alone; 5.7% walking alone. However, most patients reached motor development milestones later than the WHO standards. By the end of the observation period, the HINE-2 score in patients with SMA type I significantly increased and amounted to Me 18.50 (16.00–24.00) points, with three children achieving the maximum score. The CHOP-INTEND scale score also increased significantly and amounted to Me 60.00 (58.00–64.00) points by the end of the 2-year observation period, with 17 children (23.3%) achieving the maximum score. Before gene therapy, patients with type I SMA had low values of the amplitude [Me 0.32 mV (0.15–0.81)] and area [Me 0.80 ms×mV (0.36–1.70)] of the compound muscle action potential. 24 months after gene therapy, the values of the amplitude and area significantly increased [Me 0.80 mV (0.60–1.20) and Me 1.40 ms×mV (1.00–2.10), respectively]. However, they did not reach the electroneuromyographic values of children without neurological pathology. During clinical and electroneuromyographic assessment in the dynamics of 2-year follow-up, it was not possible to establish statistically significant differences in patients with SMA type I depending on the onset of expanded neonatal screening. Conclusion . Gene therapy in patients with SMA type I results in significant improvements in motor development. Despite persistent delays in motor skill development, a large number of patients achieved key milestones in early motor development, as demonstrated by significant increases in HINE-2 and CHOP-INTEND scores and improved electroneuromyographic parameters.

  • Open Access

    Results of a two-year comprehensive follow-up in patients with spinal muscular atrophy who received gene therapy with onasemnogen abeparvovec at the presymptomatic stage of the disease

    by Людмила Михайловна Кузенкова, Алексей Львович Куренков, Евгения Владимировна Увакина, Дарья Андреевна Фисенко, Владислав Владимирович Черников, Елена Леонидовна Семикина, София Георгиевна Попович, Бэлла Ибрагимовна Бурсагова, Оксана Валерьевна Глоба, Наталья Владимировна Андреенко, et al.

    Introduction. The use of gene therapy in patients with spinal muscular atrophy (SMA) has led to a significant improvement in the prognosis of motor development. The inclusion of SMA in the expanded neonatal screening in the Russian Federation allowed not only identifying patients as early as possible, but also gene therapy at the presymptomatic stage of the disease became available for some of them.Objective. To evaluate the effectiveness of gene therapy in real clinical practice during 2 years of follow-up of SMA patients treated with onasemnogen abeparvovec at the presymptomatic stage of the disease.Materials and methods. The study included thirty five SMA children, with a genetically verified diagnosis of SMA without developing symptoms of the disease. The diagnosis of SMA was established during the pilot project of the extended neonatal screening or from 01/01/2023 as part of the extended neonatal screening. The diagnosis was verified during DNA diagnostics. Deletion of exons 7 and/or 8 of the SMN1 gene in the homozygous state was detected in all children. All patients received gene therapy with onasemnogen abeparvovec, the average age at the time of therapy was 2.00 ± 0.94 months (95% CI 1.68–2.32), min — 1.00, max — 5.00. A comprehensive assessment was conducted of clinical (the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores), electroneuromyographic (latency, amplitude and area of the negative peak of the compound muscle action potential during electrical stimulation of the ulnar nerve on the wrist; the motor nerve conduction velocity of the ulnar nerve on the forearm) and biochemical parameters (levels of light and heavy chains of neurofilaments (NF) in blood serum in SMA patients at the presymptomatic stage before initiation of gene therapy and after 6, 12, 18, and 24 months after its implementation.Results. In our study, SMA patients at the presymptomatic stage, both before and after gene therapy, had motor development in accordance with age norms and did not significantly differ from children without neurological pathology. A comparative analysis of the electroneuromyographic parameters in SMA children and a group of healthy children revealed no statistically significant differences in patients at the presymptomatic stage of SMA on the background of gene therapy. A comparative analysis of the levels of light and heavy NF chains in the blood serum in SMA patients at the presymptomatic stage before gene therapy and 76 neurologically healthy children obtained in a recent study showed the level of light NF chains in SMA to be significantly higher (p < 0.001) — Me — 6.00, Q1; Q3 = 6.00; 31.43 pg/ml and Me — 4.00, Q1; Q3 = 2.50; 9.57 pg/ml, respectively. At the same time, the level of heavy NF chains did not significantly differ when comparing SMA patients at the presymptomatic stage before gene therapy with healthy peers. The use of onasemnogen abeparvovec in SMA patients at the presymptomatic stage led to a statistically significant decrease in the level of light chains NF in the blood serum. The maximum decrease in NF was observed 3–6 months after the gene therapy.Conclusion. Carrying out gene therapy using the onasemnogen abeparvovek in SMA patients at the presymptomatic stage made it possible to prevent the development of symptoms of the disease and achieve the main stages of motor development milestones according to WHO criteria.Compliance with ethical standards. Permission to conduct this study was obtained from the local ethics committee of the National Medical Research Center for Children’s Health (Minutes of the Local ethics committee, meeting No. 10 dated 10/06/2022).Contribution:Kuzenkova L.M., Kurenkov A.L., Uvakina E.V., Fisenko D.A. — concept and design of research, writing, editing;Chernikov V.V. — statistical data processing, editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: November 6, 2024Accepted: December 1, 2024Published: January 31, 2025


  • Open Access

    Comparative efficacy of methods for early diagnosis of myocardial involvement in Duchenne and Becker muscular dystrophies

    by Валентина Геннадьевна Каверина, Наталия Андреевна Сдвигова, Ирина Вячеславовна Сильнова, София Георгиевна Попович, Евгения Владимировна Увакина, Елена Николаевна Басаргина, Людмила Михайловна Кузенкова

    Introduction. Cardiomyopathy is the leading cause of mortality in dystrophinopathies. Standard screening methods often fail to detect early preclinical changes. The aim of the study was a comparative assessment of the diagnostic value of modern methods (global longitudinal strain — GLS, 24-hour ECG monitoring — Holter monitoring, myocardial damage biomarkers) in detecting early cardiac dysfunction.Materials and methods. A prospective cross-sectional study included thirty one patient with Duchenne/Becker muscular dystrophy (DMD/BMD). All patients underwent comprehensive assessment including echocardiography with GLS analysis, 24-hour Holter monitoring, determination of NT-proBNP and troponin I levels.Results. Reduced left ventricular ejection fraction (LVEF < 50%) was detected in 5 patients (16.1%). In patients with preserved LVEF, subclinical reduction in GLS was noted in 68.8%. Holter monitoring detected tachycardia significantly more often than a single ECG recording (p < 0.050), as well as a combination of tachycardia with reduced heart rate variability and high ventricular ectopic activity. The NT-proBNP level was significantly higher in the group with LVEF < 50% (279.8 [73.28; 844.8] vs. 60.83 [34.24; 104.5] pg/mL, p = 0.020).Conclusion. Speckle-tracking echocardiography and 24-hour Holter monitoring have significantly higher sensitivity in detecting preclinical cardiomyopathy in DMD/BMD compared to standard screening. Their combined use with the determination of NT-proBNP and troponin I allows the risk stratificating and justifying early initiation of cardioprotective therapy.Contributions:Kaverina V.G. — writing the text;Sdvigova N.A. — writing, editing the text;Silnova I.V. — writing, editing the text;Popovich S.G. — writing, editing the text;Uvakina E.V. — writing, editing the text;Basargina E.N. — conception and design of the article, writing the text, editing;Kuzenkova L.M. — conception and design of the article, writing the text, editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: December 1, 2025Accepted: December 22, 2025Published: January 31, 2026


  • Open Access

    Duchenne Muscular Dystrophy in the Republic of North Ossetia–Alania: Epidemiological Study, Diagnostic Issues, and Treatment Prospects

    by Rena Zinchenko, Inna Tebieva, Aysylu Murtazina, Sofya Ionova, Alisa Zhmurova-Kriventsova, Olga Shchagina, Elena Zinina, Yulia Gabisova, Alana Khokhova, Marina Tokazova, et al.

    Background/Objectives: The article presents data on Duchenne muscular dystrophy (DMD) in the Republic of North Ossetia-Alania (RNOA), describing the population characteristics of the disease among children in RNOA (2006–2023). Methods: The number of newborns was 172,115, with 86,057 boys from 2006 to 2023. During the reporting period, 19 families (23 patients, including 22 boys) were identified. The molecular and genetic characteristics of the patients were analyzed throughout the entire observation period, which began in 1998. Results: The prevalence of the disease was 1:3912 among newborn boys (95%CI: 1:2584–1:6242), which is slightly higher than in other regions of the Russian Federation (RF) and most countries around the world. The spectrum of DMD genetic variants in RNOA aligns with worldwide patterns but reveals differences in frequencies compared to RF data. The frequency of exon deletions in the DMD gene range from 65.0 to 70.0% (60% in RNOA vs. <50% in RF) worldwide, for duplications—9.0–11.0% globally (16% in RNOA), and for nonsense variants—9.7–26.5% worldwide (20% in RNOA). Twelve patients (41.0%) in RNOA qualified for therapy, and Translarna was prescribed in most cases. In the cohort of children, one girl was identified with classic DMD, confirmed by genetic studies. Different limitations of the study were hindered by the small cohort size, patients’ remote residences, and poor therapy compliance of our patients. Conclusions: The heterogeneity of mutation spectrum across different populations underscores the influence of ethnic background. Consequently, this study highlights the importance of population-specific studies for improving DMD care.

  • Open Access

    Trend in blood serum levels of light and heavy chains of neurofilaments in infants with spinal muscular atrophy against background of the use of gene therapy

    by Дарья Андреевна Фисенко, Людмила Михайловна Кузенкова, Алексей Львович Куренков, Елена Леонидовна Семикина, Евгения Владимировна Увакина, Владислав Владимирович Черников, Ольга Владимировна Курбатова, Tatiana M. Komyagina, Matvei V. Konyashin, София Георгиевна Попович, et al.

    Introduction. Determination of neurofilaments (NF) levels in blood serum and CSF in children with spinal muscular atrophy (SMA) may be a promising biomarker of the severity and course of the disease, as well as a way of assessing the effectiveness of pathogenetic therapy. The aim of the study was to determine the blood serum NF levels of in 0–24 months infants with SMA type I at the presymptomatic stage of the disease before and after gene therapy with onasemnogene abeparvovec (OA). Materials and methods. The study included one hundred fifty five 0–24 months infants including 76 neurologically healthy children (group II), as well as 79 patients with SMA from group I (subgroup Ia — 44 infants with SMA type I, Ib — 35 infants at the presymptomatic stage of the disease) with a diagnosis of SMA. The majority of infants with type I SMA (subgroup Ia) had 2 copies of the SMN2 gene (n = 43; 97.7%), while infants from subgroup Ib (asymptomatic patients) had 3 copies (n = 31; 88.6%). Results. The values of NF light and heavy chains in infants from group I were obtained before and after 3–6, 7–12, and 13–24 months after gene therapy with OA. The NF light chains level in the Ia subgroup before treatment was significantly higher than in the Ib subgroup (p < 0.001) and higher than in the control group (p < 0.001). The serum level of NF heavy chains in the Ia subgroup before treatment was also significantly higher than in the control group. In the Ia subgroup, there was a significant decrease (p < 0.01) in serum NF light chains 3–6 months after gene therapy (Me [Q1; Q3] — 22.97 [6.00; 48.54]) compared with the same indices before treatment (6.0 [5.92; 7.78]). Subsequently, after 7–12 months (6.15 [5.15; 7.30]) and 13–24 months (6.0 [5.7; 6.6]), stabilization of Me values was noted with a decrease in interquartile ranges. In the Ib subgroup, there was also a significant decrease (p < 0.01) in serum NF light chains levels 3–6 months after OA gene therapy (6.0 [6.00; 7.25]) compared with these indices before treatment (6.0 [6.00; 31.43]). Conclusion. Determination of the blood serum NF light and heavy chains levels in SMA patient before and after gene therapy can be regarded as a marker of the severity of the disease and the effectiveness of treatment.


  • Open Access

    The efficacy of gene therapy with onasemnogene abeparvovec in spinal muscular atrophy in young patients

    by Дарья Андреевна Фисенко, Алексей Львович Куренков, Людмила Михайловна Кузенкова, Владислав Владимирович Черников, Евгения Владимировна Увакина, София Георгиевна Попович, Бэлла Ибрагимовна Бурсагова, Луизат Муслимовна Абдуллаева, Юлия Александровна Курова, Надежда Сергеевна Адалимова, et al.

    Introduction. The advent of pathogenetic therapy has significantly changed the prognosis for spinal muscular atrophy (SMA). However, our knowledge of the pathogenetic methods of treating SMA is mostly based on the results of clinical trials, which are largely limited due to the narrow criteria for selecting patients and the short duration of the following-up. Objective. To evaluate the efficacy of onasemnogene abeparvovec gene therapy in patients with SMA type I with clinical manifestations of the disease and in children at the presymptomatic stage of the disease in real clinical practice. Materials and methods. The study included seventy nine SMA children including 42 boys (53.2%). The diagnosis was verified during DNA diagnostics. The children were divided into two subgroups, depending on whether they had symptoms of SMA at the time of inclusion in the study or not. 44 children had SMA type I with the onset of clinical symptoms before the age of 6 months of life. 35 children were at the presymptomatic stage of the disease. All patients received gene therapy with onasemnogene abeparvovec, the average age at the moment of conduction of therapy was 2.90 ± 1.74 months (95% CI: 2.51–3.29 months), min — 1.00 month, max — 7.00 months. A comprehensive assessment of clinical parameters (stages of motor development milestones according to WHO recommendations, HINE-2 and CHOP-INTEND scores) was carried out before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results. Children with SMA type I showed favour trend in motor development milestones after gene therapy. By the end of the second year of the follow-up, 88.6% of patients held their head erect and rolled from back to sides; 60.5% could sit without support, but only 10.3% were able to achieve all motor skills, but none of these children achieved them in accordance with WHO criteria. The HINE-2 score increased from Me of 2.0 (1.00–2.25) points at the initiation of therapy to Me of 20.00 (16.50-24.50) points by the end of the follow-up period. Only two children (4.5%) of this subgroup reached the maximum score of 26 points. The CHOP-INTEND score increased from Me of 30.0 (22.00–37.25) points before starting treatment to Me of 60.0 (58.0-64.0) points by 24 months of follow-up. Only 11.4% of patients with SMA type I reached the maximum score of 64 points. The majority of the presymptomatic patients in our study achieved all motor development milestones according to WHO criteria according to their age on the background of gene therapy. All children from this subgroup who were under sufficient supervision and reached the age of walking alone (23 children) had a maximum HINE-2 score of 26 points by the age of 18 months. All children from this subgroup reached the maximum CHOP-INTEND score of 64 points by the age of 6 months. Conclusion. The usage of onasemnogene abeparvovec in children with SMA type I both significantly modifies the course of the disease and improves outcomes compared with the natural history of SMA course with early onset, and the usage of gene therapy in most of the presymptomatic patients leads to the achievement of motor development milestones in accordance with WHO criteria.


  • Open Access

    Clinical case of a patient with AADC deficiency of L-aromatic amino acid decarboxylase: diagnostic route and therapeutic options

    by Евгения Владимировна Увакина, Людмила Михайловна Кузенкова, Dmitry I. Gukosyan, София Георгиевна Попович, Татьяна Владимировна Подклетнова, Anastasia A. Lyalina, Александр Алексеевич Пушков, Kirill V. Savostyanov, Yulia A. Kurova, Дарья Сергеевна Николенко, et al.

    L-aromatic amino acid decarboxylase deficiency (AADC) is a rare autosomal recessive neurometabolic disease characterized by impaired biosynthesis of neurotransmitters and manifested by disorders of movement and autonomic regulation. In the article there is discussed the diagnostic path and treatment options for a 7-year patient with severe AADC deficiency. Combination of severe neurological disorders (muscular hypotension, dystonia, hyperkinesis, oculogyric crises) and autonomic disorders (increased sweating, hypersalivation, thermoregulation disorders, nasal congestion, dyspepsia, etc.) is clearly demonstrated to require the detection of 3-O-methyldopa in dried blood spots to exclude AADC deficiency. Given the emergence of gene therapy, which is available to patients with a confirmed diagnosis of AADC deficiency in Russia within the criteria of the Circle of Kindness Foundation, it is necessary to popularize information about L-aromatic amino acid decarboxylase deficiency in the general medical community, to improve the prognosis and quality of life in AADC patients.


  • Open Access

    Trend in parameters of motor nerve conduction against the background of gene therapy in early age patients with spinal muscular atrophy

    by Дарья Андреевна Фисенко, Алексей Львович Куренков, Людмила Михайловна Кузенкова, Владислав Владимирович Черников, Евгения Владимировна Увакина, София Георгиевна Попович, Бэлла Ибрагимовна Бурсагова, Тамара Николаевна Белоусова, Natalya Yu. Kniazeva, Максим Юрьевич Новиков, et al.

    Introduction. In children with spinal muscular atrophy (SMA), reliable indicators (biomarkers) are needed to predict the disease, which could reflect the underlying process of the disease. It is believed that the parameters of motor nerve conduction studies (MNCV) (amplitude and area of the compound muscle action potential (CMAP), the motor unit number estimation) may correlate with the degree of denervation in SMA and with the severity of motor disorders. The purpose of the study. To detect the trend in MNCV parameters in SMA type I patients with clinical manifestations of the disease and children at the presymptomatic stage of the disease, against the background of treatment with onasemnogen abeparvovek. Materials and methods. The study included sixty eight SMA children, including 42 boys (53.2%). All children received gene therapy with the onasemnogen abeparvovek. 33 children were treated at the presymptomatic stage (age at the time of treatment was 2.12 ± 0.91 years (95% CI 1.80–2.45), min — 1.00, max — 5.00). In 35 SMA type I children, treatment started when clinical symptoms of the disease were already present (age at the time of treatment was 3.40 ± 1.85 years (95% CI 3.10–4.25), min — 1.00, max — 7.00). All children included in this study underwent MNCV before the start of therapy and for the next 2 years. The amplitude of the negative peak of the CMAP from the abductor digiti minimi muscle during stimulation of the ulnar nerve and nerve conduction velocity (NCV) along the distal part of the ulnar nerve were determined. Due to the fact that the values of most of the MNCV parameters did not obey the normal distribution, they were described using the values of the median (Me) and the lower and upper quartiles (Q1–Q3), minimum (min) and maximum (max). Results. In the cohort of presymptomatic patients, the CMAP and NCV parameters did not significantly differ from the normative data before the start of therapy, and against the background of treatment with onasemnogen abeparvovek, an increase in the CMAP and NCV amplitude of the was noted with increasing age in patients. The amplitude of the CMAP and NCV before treatment were 5.00 mV (4.30–5.30), min — 1.40, max — 8.00 and 33.60 m/s (32.40–38.10), min — 27.40, max — 48.90, and at the age of 13 to 24 months — 6.25 mV (5.20–6.85), min — 4.70, max — 7.80 and 55.20 m/s (52.80–57.60), min — 49.10, max — 60.30, respectively. All SMA type I patients showed a significant decrease in the amplitude of the M-response both before therapy and during 2-year follow-up after the start of treatment. The amplitude of the CMAP and NCV before treatment were 0.28 mV (0.13–0.65), min — 0.05, max — 2.20 and 31.90 m/s (27.50–35.90), min — 22.30, max — 52.00, and at the age of 13 to 24 months — 0.70 mV (0.46–1.15), min — 0.17, max — 4.60 and 48.40 m/s (43.95–50.98), min — 38.90, max — 56.10, respectively. Conclusion. When comparing the MNCV parameters in presymptomatic with SMA type I patients, significant differences were shown, which were manifested in symptomatic patients with a low amplitude of the CMAP and reduced values of NCV both before therapy and during 2-year follow-up after treatment with onasemnogen abeparvovek. Thus, conducting MNCV in children with SMA is an easily feasible study, and evaluating the amplitude of the CMAP makes it possible to reliably, albeit indirectly, verify degeneration of spinal cord motor neurons in symptomatic patients against the background of pathogenetic treatment.

  • Open Access

    The use of the drug ataluren for the treatment of patients with Duchenne muscular dystrophy in real clinical practice

    by София Георгиевна Попович, Людмила Михайловна Кузенкова, Евгения Владимировна Увакина, Татьяна Владимировна Подклетнова, Ольга Викторовна Кожевникова, Татьяна Владимировна Бушуева, Наталья Георгиевна Звонкова

    Aim. To analyze anamnestic, clinical and paraclinical indicators in patients with Duchenne muscular dystrophy (DMD) receiving pathogenetic therapy with a drug for correcting nonsense mutations in the dmd gene — ataluren (translarna), to evaluate the safety of therapy and the dynamics of motor disorders in real clinical practice against the background of use drug. Materials and methods. The study included 24 patients with DMD receiving ataluren who were hospitalized at the Center for Pediatric Psychoneurology of the National Medical Research Center for Children’s Health of the Ministry of Health of the Russian Federation for the period from January 2019 to February 2024. An analysis of anamnestic data, the most common clinical manifestations and paraclinical indicators, assessed the safety of the drug by the presence of serious adverse events leading to discontinuation of therapy, and the effectiveness of treatment using functional scales of motor activity: the “North Star” scale and the 6-minute walk test. Results. The age of onset of independent walking was 14.3 ± 2.6 months, the age of onset of the disease was 3.3 ± 2.6 years, the age of visiting a doctor was 4.25 ± 2.00 years, the age of diagnosis was 5.3 ± 2 ,3 years, age of initiation of glucocorticosteroids (GCS) — 6.3 ± 1.8 years. GCS in an adequate dose and regimen was taken by 13 (56%) patients. Cognitive, emotional-volitional and behavioral disorders were registered in 17 (70.8%) patients, excess body weight — in 6 (25%), and stiffness of the ankle joints — in 9 (37.5%).Pulmonary function was analyzed in 16 (66.6%) patients, of which a decrease was detected in 1 boy. No patient experienced a serious adverse event leading to discontinuation of ataluren. When assessing the effectiveness of treatment in a group of patients under 7 years of age (n = 11), 10 (91%) children showed improvement or stabilization of their condition according to the 6-minute walk test; in 6 (54.5%) — improvement in motor skills when analyzing scores on the “North Star” scale; in 5 (45.5%) the condition was stabilized. the group of patients over 7 years of age (n = 13), according to the 6-minute walk test, 4 (30.8%) children showed stabilization of the condition, 7 (53.8%) had disease progression, 2 (15.4%) the child entered the non-ambulatory stage. When analyzing scores on the “North Star” scale, 1 (7.7%) child showed improvement in performance, 6 (46.1%) — stabilization, 4 (30.8%) — decrease, 2 (15.4%) — loss outpatient. Conclusion. Early diagnosis of the disease and timely initiation of therapy in compliance with all standards of management of patients with DMD are crucial for maintaining motor function. Pathogenetic therapy with ataluren increases the duration of the outpatient stage, improving and/or stabilizing the motor skills of patients.